Description: Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.
Home Page: www.ultimovacs.com
Ullernchausséen 64
Oslo,
0379
Norway
Phone:
47 41 38 00 80
Officers
| Name | Title |
|---|---|
| Dr. Carlos de Sousa | Chief Executive Officer |
| Mr. Hans Vassgard Eid | Chief Financial Officer |
| Ms. Ingunn Hagen Westgaard Ph.D. | Head of Research |
| Mr. Audun Tornes | Chief Technology Officer |
| Mr. Jens Egil Torbjorn Bjorheim M.D., Ph.D. | Chief Medical Officer |
| Mr. Oivind Foss Ph.D. | Head of Clinical Operations |
| Orla Mc Callion | Head of Regulatory Affairs & QA |
| Torill Trones | Head of Office |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3844 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 17 |